187 related articles for article (PubMed ID: 32278783)
1. Re-evaluation of the Uplift Clinical Trial Using Age-Appropriate Spirometric Criteria.
Vaz Fragoso CA; Leo-Summers LS; Gill TM; McAvay GJ
Chest; 2020 Aug; 158(2):539-549. PubMed ID: 32278783
[TBL] [Abstract][Full Text] [Related]
2. Spirometric Criteria for Chronic Obstructive Pulmonary Disease in Clinical Trials of Pharmacotherapy.
Fragoso CAV; Gill TM; Leo-Summers LS; Van Ness PH
COPD; 2018 Feb; 15(1):17-20. PubMed ID: 29469677
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
Zhou Y; Zhong NS; Li X; Chen S; Zheng J; Zhao D; Yao W; Zhi R; Wei L; He B; Zhang X; Yang C; Li Y; Li F; Du J; Gui J; Hu B; Bai C; Huang P; Chen G; Xu Y; Wang C; Liang B; Li Y; Hu G; Tan H; Ye X; Ma X; Chen Y; Hu X; Tian J; Zhu X; Shi Z; Du X; Li M; Liu S; Yu R; Zhao J; Ma Q; Xie C; Li X; Chen T; Lin Y; Zeng L; Ye C; Ye W; Luo X; Zeng L; Yu S; Guan WJ; Ran P
N Engl J Med; 2017 Sep; 377(10):923-935. PubMed ID: 28877027
[TBL] [Abstract][Full Text] [Related]
5. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
Watz H; Mailänder C; May C; Baier M; Kirsten AM
Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
[TBL] [Abstract][Full Text] [Related]
6. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).
Vaz Fragoso CA; Gill TM; Leo-Summers LS; Van Ness PH
Respir Med; 2019 May; 151():27-34. PubMed ID: 31047114
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial.
Decramer M; Celli B; Tashkin DP; Pauwels RA; Burkhart D; Cassino C; Kesten S
COPD; 2004; 1(2):303-12. PubMed ID: 17136995
[TBL] [Abstract][Full Text] [Related]
9. Impact of switching to new spirometric reference equations on severity staging of airflow obstruction in COPD: a crosssectional observational study in primary care.
Sluga R; Smeele IJ; Lucas AE; Thoonen BP; Grootens-Stekelenburg JG; Heijdra YF; Schermer TR
Prim Care Respir J; 2014 Mar; 23(1):85-91. PubMed ID: 24570083
[TBL] [Abstract][Full Text] [Related]
10. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
13. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
14. Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial.
Li X; Zhou Y; Chen S; Zheng J; Zhong N; Ran P
BMJ Open; 2014 Feb; 4(2):e003991. PubMed ID: 24549160
[TBL] [Abstract][Full Text] [Related]
15. UPLIFT study - understanding potential long-term impacts on function with tiotropium - and sub-analyses. Bibliographic resume of the obtained results.
Callejas González FJ; Genovés Crespo M; Cruz Ruiz J; Godoy Mayoral R; Agustín Martínez FJ; Martínez García AJ; Tárraga López PJ
Expert Rev Respir Med; 2016 Sep; 10(9):1023-33. PubMed ID: 27176208
[TBL] [Abstract][Full Text] [Related]
16. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
17. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.
Miravitlles M; Price D; Rabe KF; Schmidt H; Metzdorf N; Celli B
Int J Chron Obstruct Pulmon Dis; 2015; 10():549-64. PubMed ID: 25834416
[TBL] [Abstract][Full Text] [Related]
18. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD.
Tashkin DP; Li N; Kleerup EC; Halpin D; Celli B; Decramer M; Elashoff R
Respir Res; 2014 Aug; 15(1):102. PubMed ID: 25175805
[TBL] [Abstract][Full Text] [Related]
19. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
20. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial.
Celli BR; Decramer M; Liu D; Metzdorf N; Asijee GM; Tashkin DP
Respir Res; 2016 May; 17(1):48. PubMed ID: 27141828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
